Showing results (31-40 of 87) with videos related to
Sort By:
Pageof 9
Plos One|October 15, 2015
Latitudinal-Related Variation in Wintering Population Trends of Greylag Geese (Anser Anser) along the Atlantic Flyway: A Response to Climate Change?Cristina Ramo, Juan A Amat, Leif Nilsson, et al.The Journal of Clinical Investigation|September 17, 2024
Targeting aryl hydrocarbon receptor functionally restores tolerogenic dendritic cells derived from patients with multiple sclerosisFederico Fondelli, Jana Willemyns, Roger Domenech-Garcia, et al.Chemosphere|November 5, 2018
Exposure of black-necked grebes (Podiceps nigricollis) to metal pollution during the moulting period in the Odiel Marshes, Southwest SpainJaime Rodríguez-Estival, Marta I Sánchez, Cristina Ramo, et al.Mediators of Inflammation|July 27, 2019
Th1Th17CM Lymphocyte Subpopulation as a Predictive Biomarker of Disease Activity in Multiple Sclerosis Patients under Dimethyl Fumarate or Fingolimod TreatmentBibiana Quirant-Sánchez, Silvia Presas-Rodriguez, María José Mansilla, et al.CNS Neuroscience & Therapeutics|April 16, 2018
Predicting therapeutic response to fingolimod treatment in multiple sclerosis patientsBibiana Quirant-Sánchez, José V Hervás-García, Aina Teniente-Serra, et al.Cytometry. Part B, Clinical Cytometry|April 6, 2017
Monitoring CD49d Receptor Occupancy: A Method to Optimize and Personalize Natalizumab Therapy in Multiple Sclerosis PatientsJoan Puñet-Ortiz, José Vicente Hervás-García, Aina Teniente-Serra, et al.Journal of Personalized Medicine|December 24, 2021
Assessing Blood-Based Biomarkers to Define a Therapeutic Window for NatalizumabJúlia Granell-Geli, Cristina Izquierdo-Gracia, Ares Sellés-Rius, et al.Journal of Clinical Medicine|May 14, 2022
Seroprevalence of SARS-CoV-2 in a Cohort of Patients with Multiple Sclerosis under Disease-Modifying TherapiesAgustín Sancho-Saldaña, Anna Gil Sánchez, Bibiana Quirant-Sánchez, et al.The Lancet. Neurology|October 23, 2021
Safety, tolerability, and activity of mesenchymal stem cells versus placebo in multiple sclerosis (MESEMS): a phase 2, randomised, double-blind crossover trialAntonio Uccelli, Alice Laroni, Rehiana Ali, et al.Neurology(R) Neuroimmunology & Neuroinflammation|September 26, 2015
Effects of diazoxide in multiple sclerosis: A randomized, double-blind phase 2 clinical trialPablo Villoslada, Alex Rovira, Xavier Montalban, et al.Pageof 9